CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.
August 14th 2019
Those with a first-degree relative diagnosed with certain blood cancers may be at an increased risk for developing the disease themselves.
August 5th 2019
A slower walking pace among older adults with blood cancer can be a sign of frailty – which could be useful to know when tailoring one’s care to increase survival and lower hospitalizations.
July 1st 2019
Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.
June 27th 2019
Newer treatments for MCL offer hope to patients living with the fast-growing and challenging-to-treat disease.
June 26th 2019
Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.
June 13th 2019
An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.
June 13th 2019
Maintenance therapy with Imbruvica appeared to be a feasible option for patients with mantle cell lymphoma, according to Dr. Reem Karmali.
June 12th 2019
Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.
May 20th 2019
While many advances have been made in the treatment landscape of MCL, the need for curative treatment options may be where future research goes.
May 17th 2019
One expert discusses the significance of newer drugs and the role they play in helping patients with relapsed or refractory disease.
May 17th 2019
A small molecule drug may help to overcome resistance to Imbruvica in patients with MCL, according to preclinical study findings from The University of Texas MD Anderson Cancer Center.
April 9th 2019
Izidore S. Lossos, M.D., discussed how questions remain on how to find the least toxic therapies that will prolong survival in both young and elderly patients with mantle cell lymphoma.
April 8th 2019
A recent clinical trial is examining the combination regimen of netupitant plus palonosetron (NEPA), with hopes that it can curb nausea and vomiting both before and after chemotherapy in patients with peripheral T-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma.
March 15th 2019
While it is an exciting time for the treatment of mantle cell lymphoma (MCL), challenges still remain, according to Andre Goy, M.D., MS.
March 14th 2019
With the evolving landscape of maintenance therapies to treat patients with lymphoma following auto-HCT, a panel consensus recommended four grade A options for physicians to utilize.
March 8th 2019
The oral blood thinner Xarelto (rivaroxaban) significantly reduced blood clots for high-risk patients with cancer being treated in the outpatient setting, according to results from the CASSINI trial.
February 17th 2019
The combination regimen demonstrated improved efficacy outcomes with a tolerable profile among patients with relapsed/refractory mantle cell lymphoma.
February 16th 2019
In patients with mantle cell lymphoma, the introduction of BTK inhibitors continues to shape the treatment landscape.
January 29th 2019
While some high-risk patients with mantle cell lymphoma may benefit from aggressive initial therapy, a recent study found that this may not be necessary for others who could benefit from more targeted therapies.
January 15th 2019
The Food and Drug Administration (FDA) has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy, according to BeiGene, the company manufacturing the agent.
December 26th 2018
The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.
December 11th 2018
Measuring circulating tumor DNA in the blood of patients with advanced mantle cell lymphoma may be a viable way to predict how well they will respond to specific therapies.
December 10th 2018
Treatment with Velcade (bortezomib) following induction chemotherapy and stem cell transplantation seemed safe and effective for untreated patients with mantle cell lymphoma, encouraging further evaluation for more active, less toxic targeted agents.
December 7th 2018
A recent study looked at a new combination to determine what would happen if untreated patients eligible for transplant were given alternating cycles of Rituxan plus bendamustine and Rituxan plus cytarabine as induction therapy. The study pooled findings from two clinical trials and real-world experience.
November 13th 2018
Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.
November 13th 2018
Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
November 12th 2018
Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.
October 26th 2018
The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.